Program
obecabtagene autoleucel
Also written as “AUTO1”, “Obecabtagene autoleucel (obe-cel)” and “Obecabtagene autoleucel”.
Its studies are mostly in Lupus Nephritis · Multiple Sclerosis, Chronic Progressive · Lupus Erythematosus, Systemic, led by Autolus.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Autolus | 55 open or running | phase 2since May 12, 2020 | May 12, 2020 | Sep 2027phase 1 · NCT06333483 |
Also a collaborator on its studies: PPD Development, LP.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 12, 2020First study: phase 2 study in RecurrenceFirst studyNCT04404660 · 153 enrolled · United States, Spain, United Kingdom
- Dec 8, 2023Phase 1 study in RecurrenceNCT06173518 · 30 planned · United States, Spain, United Kingdom
- Mar 6, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06333483 · 16 enrolled · Spain, United Kingdom
- May 13, 2025Phase 2 study in Lupus NephritisNCT07053800 · 35 planned · United States, Brazil, Greece and more
- Aug 18, 2025Phase 1 study in Multiple Sclerosis, Chronic ProgressiveNCT07139743 · 24 planned · United States, Spain, United Kingdom
Ahead
- Sep 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06333483
- Nov 2027Primary completion: phase 1 study in RecurrenceNCT06173518
- Aug 2028Primary completion: phase 2 study in Lupus NephritisNCT07053800
- Jun 30, 2029Primary completion: phase 2 study in RecurrenceNCT04404660
TargetBeta
“A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with immunostimulating and antineoplastic activities”NCIt, by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07139743Multiple Sclerosis, Chronic Progressive · United States, Spain, United Kingdom | 1 | Recruiting | Aug 15, 2029 | 24 |
| NCT07053800Lupus Nephritis · United States, Brazil, Greece and more | 2 | Recruiting | Aug 2028 | 35 |
| NCT06333483Lupus Erythematosus, Systemic · Spain, United Kingdom | 1 | Active, not recruiting | Sep 2027 | 16 |
| NCT06173518Recurrence · United States, Spain, United Kingdom | 1 | Recruiting | Nov 2027 | 30 |
| NCT04404660Recurrence · United States, Spain, United Kingdom | 2 | Active, not recruiting | Jun 30, 2029 | 153 |
How it is read
Names in the registry
- “AUTO1”, 2 entries
- “Obecabtagene autoleucel (obe-cel)”, 2 entries
- “Obecabtagene autoleucel”, 1 entry
Conditions, from the studies’ own filings
- Lupus Nephritis, 1 study
- Multiple Sclerosis, Chronic Progressive, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.